This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, J. K. Articles by Adams, M. R. Search for Related Content PubMed PubMed Citation Articles by Williams, J. K. Articles by Adams, M. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ESTROGENIC SUBSTANCES, CONJUGATED NITROGLYCERIN TAMOXIFEN

(Circulation. 1997;96:1970-1975.)
© 1997 American Heart Association, Inc.

Articles

Contrasting Effects of Conjugated Estrogens and Tamoxifen on Dilator Responses of Atherosclerotic Epicardial Coronary Arteries in Nonhuman Primates

J. Koudy Williams, DVM; Erika K. Honoré, DVM, MPH; ; Michael R. Adams, DVM

From the Comparative Medicine Clinical Research Center and the Department of Comparative Medicine, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC. Dr Honoré's present address is Department of Medicine and Physiology, Southwest Foundation for Biomedical Research, San Antonio, Tex.

Correspondence to J. Koudy Williams, DVM, Department of Comparative Medicine, Bowman Gray School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1040. E-mail kwilliams{at}cpm.bgsm.edu

Background Estrogens have been shown to improve dilator responses of atherosclerotic coronary arteries. Tamoxifen is a mixed estrogen agonist/antagonist with as yet unexplored effects on vascular function. Therefore, the goal of this study was to compare the effects of conjugated equine estrogens (CEEs) with those of tamoxifen on epicardial coronary artery dilator responses in atherosclerotic, ovariectomized monkeys.

Methods and Results Fifty ovariectomized cynomolgus monkeys were fed an atherogenic diet for 34 months. During this time, monkeys were assigned to one of three treatment groups: (1) control, no hormone replacement (n=15); (2) CEEs mixed in the diet at a dose of 0.043 mg · kg^-1 · d^-1 (n=14); or (3) tamoxifen mixed in the diet at a dose of 1.3 mg · kg^-1 · d^-1 (n=21). Quantitative angiography was used to measure coronary artery dilator responses to intracoronary infusions of acetylcholine (10^-8, 10^-7, and 10^-6 mol/L) and nitroglycerin (15 µg/min). Coronary arteries of the tamoxifen-treated group constricted in response to high-dose acetylcholine (-5.4± 2.3%, P<.05 versus control), whereas those of the CEE group did not (P>.05 versus control). Conversely, arteries from the CEE group dilated in response to nitroglycerin (9.1±2.1%, P<.05 versus control), whereas those from the tamoxifen group did not (P>.05 versus control). Statistical adjustments for variations in plaque extent (determined subsequently after necropsy) and plasma lipoproteins did not alter the results.

Conclusions Tamoxifen has primarily estrogen-antagonistic effects on epicardial coronary artery dilator responses in atherosclerotic monkeys. Results implicate the estrogen receptor as a modulator of coronary artery dilator responses in ovariectomized, atherosclerotic monkeys.

Key Words: atherosclerosis • arteries • hormones • tamoxifen • vasculature

This article has been cited by other articles:

				P. Ouyang, E. D. Michos, and R. H. Karas Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1741 - 1753. [Abstract] [Full Text] [PDF]

				T. S Mikkola and T. B Clarkson Estrogen replacement therapy, atherosclerosis, and vascular function Cardiovasc Res, February 15, 2002; 53(3): 605 - 619. [Abstract] [Full Text] [PDF]

				R. K. Dubey, S. Oparil, B. Imthurn, and E. K. Jackson Sex hormones and hypertension Cardiovasc Res, February 15, 2002; 53(3): 688 - 708. [Abstract] [Full Text] [PDF]

				R. Campisi, L. Nathan, M. H. Pampaloni, H. Schoder, J. W. Sayre, G. Chaudhuri, and H. R. Schelbert Noninvasive Assessment of Coronary Microcirculatory Function in Postmenopausal Women and Effects of Short-Term and Long-Term Estrogen Administration Circulation, January 29, 2002; 105(4): 425 - 430. [Abstract] [Full Text] [PDF]

				N. N. Chan, R. J. MacAllister, H. M. Colhoun, P. Vallance, and A. D. Hingorani Changes in Endothelium-Dependent Vasodilatation and {{alpha}}-Adrenergic Responses in Resistance Vessels during the Menstrual Cycle in Healthy Women J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2499 - 2504. [Abstract] [Full Text] [PDF]

				R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]

				S. E. Reis, J. P. Costantino, D. L. Wickerham, E. Tan-Chiu, J. Wang, and M. Kavanah Cardiovascular Effects of Tamoxifen in Women With and Without Heart Disease: Breast Cancer Prevention Trial J Natl Cancer Inst, January 3, 2001; 93(1): 16 - 21. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and R. H. Karas The Protective Effects of Estrogen on the Cardiovascular System N. Engl. J. Med., June 10, 1999; 340(23): 1801 - 1811. [Full Text] [PDF]

				D. Somjen, F. Kohen, A. Jaffe, Y. Amir-Zaltsman, E. Knoll, and N. Stern Effects of Gonadal Steroids and Their Antagonists on DNA Synthesis in Human Vascular Cells Hypertension, July 1, 1998; 32(1): 39 - 45. [Abstract] [Full Text] [PDF]